Goldman Sachs
BCAX

Goldman Sachs’s Bicara Therapeutics BCAX Stock Holding History

Goldman Sachs’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.1M Buy
558,964
+6,633
+1% +$114K ﹤0.01% 2989
2025
Q4 		$9.3M Buy
552,331
+319,570
+137% +$5.46M ﹤0.01% 3160
2025
Q3 		$3.68M Buy
232,761
+80,904
+53% +$906K ﹤0.01% 3930
2025
Q2 		$1.41M Buy
151,857
+26,162
+21% +$312K ﹤0.01% 4443
2025
Q1 		$1.64M Sell
125,695
-54,054
-30% -$718K ﹤0.01% 4321
2024
Q4 		$3.13M Buy
179,749
+77,854
+76% +$1.62M ﹤0.01% 3914
2024
Q3 		$2.6M Buy
+101,895
New +$2.6M ﹤0.01% 3920

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Goldman Sachs's BCAX Position: Q1 2026 in Review

Goldman Sachs increased its Bicara Therapeutics (BCAX) stake by 1.2% in Q1 2026, buying an estimated $114K and bringing the position to 558,964 shares worth $11.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2989.

Goldman Sachs first reported a position in BCAX in Q3 2024 and has held it in 7 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Goldman Sachs held 558,964 shares of Bicara Therapeutics worth $11.1M as of Q1 2026.
  • Goldman Sachs bought 6,633 Bicara Therapeutics shares in Q1 2026, an estimated $114K.
  • Bicara Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2989 holding.
  • Goldman Sachs first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.